This study is in progress, not accepting new patients
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Sarah Larson
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Sarah Larson
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 19 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pfizer
- Links
- To obtain contact information for a study center near you, click here. Open Science Registry
- ID
- NCT04649359
- Phase
- Phase 2 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- About 188 people participating
- Last Updated